Kevin M. Spencer

Kevin M. Spencer's AcademicInfluence.com Rankings

Kevin M. Spencer

Engineering

#6589

World Rank

#7925

Historical Rank

Biomedical Engineering

#599

World Rank

#609

Historical Rank

engineering Degrees

Kevin M. Spencer

Philosophy

#8907

World Rank

#12380

Historical Rank

Logic

#5916

World Rank

#7373

Historical Rank

philosophy Degrees

Download Badge

Engineering
Philosophy

Kevin M. Spencer's Degrees

Doctorate Medicine Stanford University

Why Is Kevin M. Spencer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Kevin M. Spencer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A (1999) (604)
Multicenter study of first‐trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk‐orientated two‐stage first‐trimester screening (2005) (477)
Analytical Reviews in Clinical Biochemistry: The Estimation of Creatinine (1986) (386)
First trimester maternal serum free β human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications (2000) (371)
Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one‐stop clinic: a review of three years prospective experience (2003) (325)
First‐trimester screening for trisomy 21 by free beta‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A: impact of maternal and pregnancy characteristics (2008) (269)
One‐stop clinic for assessment of risk for trisomy 21 at 11–14 weeks: a prospective study of 15 030 pregnancies (2002) (259)
Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis (2015) (247)
Prediction of pregnancy complications by first‐trimester maternal serum PAPP‐A and free β‐hCG and with second‐trimester uterine artery Doppler (2005) (238)
Screening for triploidy by fetal nuchal translucency and maternal serum free β‐hCG and PAPP‐A at 10–14 weeks of gestation (2000) (232)
First‐trimester maternal serum PP‐13, PAPP‐A and second‐trimester uterine artery Doppler pulsatility index as markers of pre‐eclampsia (2007) (232)
Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis (2013) (224)
Low levels of maternal serum PAPP‐A in the first trimester and the risk of pre‐eclampsia (2008) (206)
Free Beta Human Choriogonadotropin in Down's Syndrome Screening: A Multicentre Study of its Role Compared with other Biochemical Markers (1992) (183)
First‐trimester ADAM12 and PAPP‐A as markers for intrauterine fetal growth restriction through their roles in the insulin‐like growth factor system (2007) (168)
First‐trimester biochemical markers of aneuploidy and the prediction of small‐for‐gestational age fetuses (2008) (162)
Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies. (2005) (159)
Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one‐stop clinic: a review of three years experience (2003) (158)
Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free β‐hCG and PAPP‐A at 11 to 14 weeks (2003) (155)
Prenatal Detection of Down Syndrome using Massively Parallel Sequencing (MPS): a rapid response statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, 24 October 2011 (2012) (152)
Evaluation of an assay of the free beta-subunit of choriogonadotropin and its potential value in screening for Down's syndrome. (1991) (150)
Screening for trisomy 21 in twin pregnancies in the first trimester using free β‐hCG and PAPP‐A, combined with fetal nuchal translucency thickness (2000) (149)
Predicting complications of pregnancy with first‐trimester maternal serum free‐βhCG, PAPP‐A and inhibin‐A (2003) (141)
Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro‐Caribbean populations (2005) (137)
Women as moral pioneers? Experiences of first trimester antenatal screening. (2005) (131)
One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester (2000) (130)
First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. (2001) (125)
Prediction of pre‐eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy‐associated plasma protein‐A, free β‐human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation (2006) (124)
First‐trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery (2008) (119)
Maternal weight correction of maternal serum PAPP‐A and free β‐hCG MoM when screening for trisomy 21 in the first trimester of pregnancy (2003) (119)
Maternal serum free β‐hCG and PAPP‐A in fetal sex chromosome defects in the first trimester (2000) (116)
Delta‐NT or NT MoM: which is the most appropriate method for calculating accurate patient‐specific risks for trisomy 21 in the first trimester? (2003) (116)
Free β-hCG as first-trimester marker for fetal trisomy (1992) (114)
Screening for trisomy 18 by fetal nuchal translucency and maternal serum free β ‐hCG and PAPP‐A at 10–14 weeks of gestation (1999) (111)
First‐trimester combined screening for trisomy 21 at 7–14 weeks' gestation (2010) (109)
First‐trimester markers for the prediction of pre‐eclampsia in women with a‐priori high risk (2010) (108)
A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free β‐hCG and PAPP‐A (2002) (108)
The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities (2000) (101)
First‐trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death (2006) (98)
Screening for trisomy 13 by fetal nuchal translucency and maternal serum free β‐hCG and PAPP‐A at 10–14 weeks of gestation (2000) (97)
Second‐trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome (2000) (96)
The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy (2004) (94)
Aneuploidy screening in the first trimester (2007) (92)
ADAM12s in maternal serum as a potential marker of pre‐eclampsia (2008) (92)
Second trimester prenatal screening for Down's syndrome using alpha‐fetoprotein and free beta hCG: a seven year review (1999) (90)
First trimester maternal serum placental protein 13 for the prediction of pre‐eclampsia in women with a priori high risk (2009) (89)
Temporal Changes in Maternal Serum Biochemical Markers of Trisomy 21 across the First and Second Trimester of Pregnancy (2002) (88)
Fetal heart rate in chromosomally abnormal fetuses (2000) (83)
Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free β‐hCG and PAPP‐A at 11 + 0 to 13 + 6 weeks (2006) (82)
First‐trimester free beta (hCG) screening for Down syndrome (1993) (81)
Screening for trisomy 21 in twin pregnancies in the first trimester: an update of the impact of chorionicity on maternal serum markers (2008) (80)
Down's syndrome screening in multiple pregnancies using alpha‐fetoprotein and free beta hCG (1994) (79)
Prospective study of prenatal screening for Down's syndrome with free beta human chorionic gonadotrophin. (1993) (78)
First‐trimester biochemical screening for fetal chromosome abnormalities and neural tube defects (1993) (78)
Maternal serum inhibin‐A and activin‐A levels in the first trimester of pregnancies developing pre‐eclampsia (2008) (76)
Second‐trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre‐eclampsia (2007) (76)
Cross-trimester repeated measures testing for Down's syndrome screening: an assessment. (2010) (76)
First Trimester Biochemical Screening for Trisomy 21: The Role of Free Beta hCG, Alpha Fetoprotein and Pregnancy Associated Plasma Protein A (1994) (73)
Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocol (2014) (73)
First‐Trimester Maternal Serum Levels of Placenta Growth Factor as Predictor of Preeclampsia and Fetal Growth Restriction (2001) (72)
On being at higher risk: a qualitative study of prenatal screening for chromosomal anomalies. (2006) (71)
SECOND‐TRIMESTER DIMERIC INHIBIN‐A IN DOWN'S SYNDROME SCREENING (1996) (70)
One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. (2001) (70)
Maternal serum free beta hCG screening: Results of studies including 480 cases of down syndrome (1994) (70)
ADAM 12 as a second‐trimester maternal serum marker in screening for Down syndrome (2006) (65)
Aneuploidy screening: a position statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, January 2011 (2011) (63)
A reassessment of biochemical marker distributions in trisomy 21‐affected and unaffected twin pregnancies in the first trimester (2011) (62)
Age related detection and false positive rates when screening for Down's Syndrome in the first trimester using fetal nuchal translucency and maternal serum free βhCG and PAPP‐A (2001) (61)
The influence of maternal insulin‐dependent diabetes on fetal nuchal translucency thickness and first‐trimester maternal serum biochemical markers of aneuploidy (2005) (60)
The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free β‐hCG and PAPP‐A at 10–14 weeks of gestation (2000) (59)
The influence of smoking on maternal serum AFP and free beta hCG levels and the impact on screening for Down syndrome (1998) (58)
Elevated Levels of Maternal Serum Inhibin Immunoreactivity in Second Trimester Pregnancies Affected by Down's Syndrome (1993) (58)
Stability of intact chorionic gonadotropin (hCG) in serum, liquid whole blood, and dried whole-blood filter-paper spots: impact on screening for Down syndrome by measurement of free beta-hCG subunit. (1993) (55)
First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markers (2010) (54)
Screening for Down's syndrome using serum alpha fetoprotein: a retrospective study indicating caution. (1985) (53)
Early Detection of Down's Syndrome Using Free Beta Human Choriogonadotropin (1992) (51)
Factors affecting women's preference for type of prenatal screening test for chromosomal anomalies (2004) (50)
The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome (2003) (50)
The influence of smoking on maternal serum PAPP‐A and free beta hCG levels in the first trimester of pregnancy (1999) (50)
Screening for trisomy 21 in twin pregnancies in the first trimester: does chorionicity impact on maternal serum free β‐hCG or PAPP‐A levels? (2001) (49)
First‐trimester maternal placental protein 13 levels in pregnancies resulting in adverse outcomes (2008) (47)
Sonographic screening for trisomy 13 at 11 to 13(+6) weeks of gestation. (2006) (47)
Maternal serum biochemistry at 11–13+6 weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening (2005) (47)
Higher Median Levels of Free β-hCG and PAPP-A in the First Trimester of Pregnancy in a Chinese Ethnic Group (2005) (47)
Age‐standardisation when target setting and auditing performance of Down syndrome screening programmes (2004) (46)
What is the true fetal loss rate in pregnancies affected by trisomy 21 and how does this influence whether first trimester detection rates are superior to those in the second trimester? (2001) (46)
First‐trimester placental growth factor as a marker for hypertensive disorders and SGA (2010) (45)
ADAM 12 as a first‐trimester maternal serum marker in screening for Down syndrome (2006) (45)
Prenatal screening for trisomy 18 with free beta human chorionic gonadotrophin as a marker. (1993) (45)
The use of serum inhibin A and activin A levels in predicting the outcome of 'pregnancies of unknown location'. (2009) (41)
The influence of parity and gravidity on first trimester markers of chromosomal abnormality (2000) (39)
The influence of fetal sex in screening for Down syndrome in the second trimester using AFP and free β‐hCG (2000) (39)
Higher median levels of free beta-hCG and PAPP-A in the first trimester of pregnancy in a Chinese ethnic group. Implication for first trimester combined screening for Down's syndrome in the Chinese population. (2006) (39)
Dose dependency between cigarette consumption and reduced maternal serum PAPP‐A levels at 11–13+6 weeks of gestation (2007) (38)
The impact of fetal gender on first trimester nuchal translucency and maternal serum free β‐hCG and PAPP‐A MoM in normal and trisomy 21 pregnancies (2009) (38)
First Trimester Sex Hormone-Binding Globulin and Subsequent Development of Preeclampsia or Other Adverse Pregnancy Outcomes (2005) (38)
ADAM12 as a marker of trisomy 18 in the first and second trimester of pregnancy (2007) (38)
A re‐evaluation of the influence of maternal insulin‐dependent diabetes on fetal nuchal translucency thickness and first‐trimester maternal serum biochemical markers of aneuploidy (2010) (38)
First trimester maternal serum screening for Down's syndrome: an evaluation of the DPC Immulite 2000 free β-hCG and pregnancy-associated plasma protein-A assays (2005) (37)
FIRST‐TRIMESTER URINE FREE BETA hCG, BETA CORE, AND TOTAL OESTRIOL IN PREGNANCIES AFFECTED BY DOWN'S SYNDROME: IMPLICATIONS FOR FIRST‐TRIMESTER SCREENING WITH NUCHAL TRANSLUCENCY AND SERUM FREE BETA hCG (1997) (37)
Screening for Down syndrome (2014) (37)
PAPP‐A and free ß‐hCG stability in first trimester serum using PerkinElmer AutoDELFIA® and DELFIA® Xpress systems (2010) (37)
Free beta-hCG as first-trimester marker for fetal trisomy. (1992) (36)
First-trimester maternal serum activin A in pre-eclampsia and fetal growth restriction (2004) (36)
First‐trimester combined screening for trisomy 21 in a predominantly Chinese population (2007) (36)
Is maternal serum total hCG a marker of trisomy 21 in the first trimester of pregnancy? (2000) (36)
First trimester maternal serum placenta growth factor (PIGF)concentrations in pregnancies with fetal trisomy 21 or trisomy 18 (2001) (34)
URINE FREE BETA hCG AND BETA CORE IN PREGNANCIES AFFECTED BY DOWN'S SYNDROME (1996) (33)
Dual Analyte Immunoassay in Neural Tube Defect and Down's Syndrome Screening: Results of a Multicentre Clinical Trial (1993) (33)
Increased total cell‐free DNA in the serum of pregnant women carrying a fetus affected by trisomy 21 (2003) (33)
BIOCHEMICAL MARKERS OF TRISOMY 21 IN AMNIOTIC FLUID (1997) (32)
Maternal serum level of placental growth factor in diabetic pregnancies. (2004) (30)
First trimester maternal serum biochemical markers of aneuploidy in pregnancies with abnormally invasive placentation (2015) (29)
The association between gestational diabetes mellitus and first trimester aneuploidy screening markers (2013) (28)
Placental Protein-13 and Pregnancy-Associated Plasma Protein-A as First Trimester Screening Markers for Hypertensive Disorders and Small for Gestational Age Outcomes (2011) (28)
FREE BETA hCG SCREENING OF HYDROPIC AND NON‐HYDROPIC TURNER SYNDROME PREGNANCIES (1996) (27)
Dual Analyte Immunoassay—a New Approach to Neural Tube Defect and Down's Syndrome Screening (1992) (27)
First‐trimester ADAM12s as early markers of trisomy 21: a promise still unfulfilled? (2008) (27)
Physiological distribution of placental growth factor and soluble Flt‐1 in early pregnancy (2008) (26)
The influence of different sample collection types on the levels of markers used for Down's syndrome screening as measured by the Kryptor Immunosassay system (2003) (26)
Accuracy of Down syndrome risks produced in a first‐trimester screening programme incorporating fetal nuchal translucency thickness and maternal serum biochemistry (2002) (26)
Maternal serum levels of dimeric inhibin A in pregnancies affected by trisomy 21 in the first trimester (2001) (26)
The influence of gravidity on Down's syndrome screening with free beta hCG (1995) (26)
Free β-Chorionic Gonadotropin: A Cross-Reactivity Study of Two Immunometric Assays Used in Prenatal Maternal Serum Screening for Down's Syndrome (1993) (25)
Between pregnancy biological variability of first trimester markers of Down syndrome: implications for screening in subsequent pregnancies (2001) (25)
Accuracy of self‐reported smoking status in first trimester aneuploidy screening (2013) (25)
First trimester maternal serum placental growth factor in trisomy 21 pregnancies (2010) (24)
Maternal serum ADAM12s in the late first trimester of pregnancies with Trisomy 21 (2008) (24)
First trimester markers of trisomy 21 and the influence of maternal cigarette smoking status (2000) (23)
Maternal serum ADAM12s as a potential marker of trisomy 21 prior to 10 weeks of gestation (2008) (23)
First trimester screening for Down syndrome using free β hCG, total hCG and PAPP‐A: an exploratory study (2007) (22)
Stability of first trimester placental growth factor in serum and whole blood (2011) (22)
Frequency and clinical consequences of extremely high maternal serum PAPP‐A levels (2003) (22)
BETWEEN‐PREGNANCY BIOLOGICAL VARIABILITY OF MATERNAL SERUM ALPHA‐ FETOPROTEIN AND FREE BETA hCG: IMPLICATIONS FOR DOWN SYNDROME SCREENING IN SUBSEQUENT PREGNANCIES (1997) (21)
First trimester prenatal diagnosis of trisomy 21 in discordant twins using fetal nuchal translucency thickness and maternal serum free β‐hCG and PAPP‐A (2000) (21)
Second trimester levels of pregnancy associated plasma protein‐A in cases of trisomy 18 (1999) (20)
Screening for Down's syndrome. The role of intact hCG and free subunit measurement. (1993) (19)
PP13 as a marker of pre-eclampsia: A two platform comparison study. (2011) (19)
A link between high serum levels of human chorionic gonadotrophin and chorionic expression of its mature functional receptor (LHCGR) in Down's syndrome pregnancies (2005) (19)
Comparison of Down's Syndrome Screening Strategies in Asians combining Serum Free Beta‐hCG and Alpha‐fetoprotein with Maternal Age (1997) (18)
Biochemical screening for Down syndrome in pregnancies following renal transplantation (2002) (18)
Maternal Serum CA125 is Not a Second Trimester Marker for Down's Syndrome (1991) (18)
Evolution of an Inhibin a ELISA Method: Implications for Down's Syndrome Screening (1998) (17)
Maternal serum ADAM12s as a marker of rare aneuploidies in the first or second trimester of pregnancy (2007) (17)
Free α-subunit of human chorionic gonadotropin in Down syndrome (1993) (17)
Second-trimester sex hormone-binding globulin and subsequent development of pre-eclampsia. (2004) (17)
Between pregnancy biological variability of first trimester markers of Down syndrome and the implications for screening in subsequent pregnancies: an issue revisited (2002) (16)
The use of nuchal translucency measurement and second trimester biochemical markers in screening for Down's Syndrome (2001) (16)
Early first‐trimester maternal serum placental growth factor in trisomy 21 pregnancies (2011) (16)
Screening for chromosomal anomalies in the first trimester: does repeat maternal serum screening improve detection rates? (2002) (16)
Toward the optimal protocol for Down syndrome screening. (1996) (16)
Maternal serum PP13 and PAPP-A in first trimester, and doppler in second trimester, as markers of early pre-eclampsia (2005) (16)
Uterine artery Doppler and mid-trimester maternal plasma homocysteine in subsequent pre-eclampsia. (2004) (16)
Letter. Response to: Wald, N.J. and Hackshaw, A.K. (1997). Combining ultrasound and biochemistry in first‐trimester screening for Down's syndrome, Prenat. Diagn., 17, 821–829 (1998) (16)
Is prostate-specific antigen a marker for pregnancies affected by Down syndrome? (1998) (16)
Effect of gestational age on first trimester maternal serum prenatal screening correction factors for ethnicity and IVF conception (2013) (16)
Maternal serum alpha‐fetoprotein in fetal neural tube and abdominal wall defects at 10 to 14 weeks of gestation (1997) (15)
Accuracy of Down's Syndrome Risks Produced in a Prenatal Screening Program (1999) (15)
First trimester maternal serum AFP and total hCG in aneuploidies other than trisomy 21 (2000) (15)
Is maternal renal disease a cause of elevated free β‐hCG in first trimester aneuploidy screening? (2009) (15)
Maternal Serum ADAM-12 as a Potential Marker for Different Adverse Pregnancy Outcomes (2010) (14)
Down syndrome screening marker levels in women with a previous aneuploidy pregnancy (2005) (13)
Maternal serum levels of total activin‐A in first‐trimester trisomy 21 pregnancies (2001) (13)
Uptake of prenatal screening for chromosomal anomalies: impact of test results in a previous pregnancy (2002) (13)
Urinary free beta hCG, beta core fragment and total oestriol as markers of Down syndrome in the second trimester of pregnancy (1999) (12)
Evaluation of a dried blood spot assay to measure prenatal screening markers pregnancy-associated plasma protein a and free β-subunit of human chorionic gonadotropin. (2013) (12)
Uterine artery Doppler and mid-trimester maternal plasma homocysteine in subsequent pre-eclampsia (2004) (12)
Inside ‘Inside View’: reflections on stimulating debate and engagement through a multimedia live theatre production on the dilemmas and issues of pre‐natal screening policy and practice (2011) (12)
ADAM12‐s in coelomic fluid and maternal serum in early pregnancy (2006) (12)
First and Second Trimester Markers of Fetal Aneuploidy in Pregnant Women with HIV Infection (2010) (12)
Maternal serum hyperglycosylated human chorionic gonadotrophin (HhCG) in the first trimester of pregnancies affected by Down syndrome, using a sialic acid‐specific lectin immunoassay (2002) (11)
ADAM‐12 stability in first trimester maternal serum (2010) (11)
First-Trimester Screening for Trisomy 21 by Free Beta-Human Chorionic Gonadotropin and Pregnancy-Associated Plasma Protein-A : Impact of Maternal and Pregnancy Characteristics (2008) (11)
Prenatal diagnosis of trisomy 21 in monozygotic twins with increased nuchal translucency and abnormal serum biochemistry. (1997) (10)
Second‐trimester levels of pregnancy‐associated plasma protein‐A and free β‐hCG in pregnancies with trisomy 13 (2005) (10)
Non-Invasive Screening Tests (2005) (10)
Nuchal translucency and gestational age. (2004) (10)
First trimester maternal serum alpha‐fetoprotein is not raised in pregnancies with open spina bifida (2014) (10)
Maternal serum CA 19–9 and CA 15–3 levels in pregnancies affected by trisomy 21 (2012) (10)
The stability of free‐β human chorionic gonadotrophin and pregnancy‐associated plasma protein‐A in first trimester dried blood spots (2011) (9)
Maternal serum total hCG and free β‐hCG in the first trimester from trisomy 21 pregnancies (2000) (9)
First trimester detection of trisomy 16 using combined biochemical and ultrasound screening (2014) (9)
Amniotic Fluid and Maternal Serum Levels of CA125 in Pregnancies affected by Down Syndrome: a Re‐evaluation of the Role of CA125 in Down Syndrome Screening (1997) (9)
Detection of maternal serum hCG glycoform variants in the second trimester of pregnancies affected by Down syndrome using a lectin immunoassay (2003) (8)
Risk of Down's syndrome and amniocentesis rate. (1992) (8)
Point-of-care screening for chromosomal anomalies in the first trimester of pregnancy. (2002) (8)
Screening in the presence of a vanished twin: Nuchal translucency or combined screening test? (2011) (8)
Correction of first trimester biochemical aneuploidy screening markers for smoking status: influence of gestational age, maternal ethnicity and cigarette dosage (2013) (8)
Free beta-chorionic gonadotropin: a cross-reactivity study of two immunometric assays used in prenatal maternal serum screening for Down's syndrome. (1993) (8)
Maternal serum activin A and inhibin A in trisomy 18 pregnancies at 10–14 weeks (2001) (8)
Utility of unconjugated estriol in screening for Down syndrome is not proven. (1993) (7)
Coelomic Fluid Leptin Concentration in Normal First-Trimester Pregnancies and Missed Miscarriages (2005) (7)
Prenatal screening for trisomy 18 with free β human chorionic gonadotrophin as a marker (1994) (7)
Can we afford screening for neural tube defects? (1985) (7)
Maternal plasma levels of follistatin‐related gene protein in the first trimester of pregnancies with Down syndrome (2010) (7)
PP13 stability in first trimester maternal serum and whole blood (2010) (7)
The relationship between maternal body mass, smoking status and ethnicity and first trimester nuchal translucency thickness (2011) (7)
First trimester intact hCG as an early marker of trisomy 21: a promise unrecognised? (2008) (7)
First trimester maternal serum placental growth factor levels in twin pregnancies (2013) (6)
Trends in prenatal diagnosis of Down's syndrome. (1993) (6)
A Comparison of Numerical Risk Computational Techniques in Screening for Down's Syndrome (1998) (6)
The Measurement of Amniotic Fluid α2 Macroglobulin by Fixed Time Kinetic Immunoturbidimetry (1983) (5)
First-Trimester Markers of Aneuploidy and the Prediction of Small-for-Gestational Age Fetuses (2008) (5)
Median values and maternal weight specific to the ethnic group should be used (1996) (5)
Early vaginal bleeding has no impact on markers used in first trimester aneuploidy screening (2010) (5)
Maternal serum screening marker levels in women with a previous aneuploidy pregnancy (2009) (5)
Second-trimester sex hormone-binding globulin and subsequent development of pre-eclampsia (2004) (5)
The use of free β‐hCG in antenatal screening for Down's syndrome (1994) (5)
A Comparison of Two Immunoassay Methods for the Measurement of Maternal Serum Placental Growth Factor in Early Pregnancy (2012) (5)
A technical and clinical evaluation of a new assay for inhibin A and its use in second trimester Down syndrome screening (2016) (4)
First trimester detection of double aneuploidy involving autosomes and sex chromosomes using combined biochemical and ultrasound screening (2013) (4)
The effect of Rhesus status on first‐trimester pregnancy screening markers free β human chorionic gonadotropin, pregnancy‐associated plasma protein‐A and nuchal translucency (2009) (4)
Maternal serum placental growth factor in second trimester trisomy 21 pregnancies (2012) (4)
Antenatal maternal serum profiles. (1994) (4)
Analytical goal setting in aneuploidy screening: within person biological variability of first trimester biochemical markers (2013) (4)
Antenatal Diagnosis of Neural Tube Defects Using a Coated Bead Immunoassay for Acetylcholinesterase in Amniotic Fluid (1988) (4)
Neurone Specific Enolase in Amniotic Fluid: A Potential Marker of Anencephaly (1988) (4)
Antenatal screening for Down's syndrome. (1992) (4)
Precise gaussian distribution functions of maternal serum alpha-fetoprotein and free beta-subunit of human chorionic gonadotropin for trisomy 21 screening: improved accuracy for patient counseling. (1997) (3)
Experiences of first trimester antenatal screening in a one-stop clinic (2008) (3)
Free alpha-subunit of human chorionic gonadotropin in Down syndrome. (1993) (3)
Second-trimester maternal urine human chorionic gonadotrophin beta-core fragment concentrations in Asian pregnancies with fetal chromosomal abnormalities. (1999) (3)
First-Trimester Biochemical Markers of Aneuploidy and the Prediction of Small-for-Gestational Age Fetuses (2009) (3)
Maternal serum ADAM 12 s as a marker of rare aneuploidies in the first or second trimester of pregnancy (2007) (3)
First trimester CA 125 and Down's syndrome (1991) (3)
AGE‐INDEPENDENT INDICES IN SECOND‐TRIMESTER SERUM SCREENING FOR DOWN'S SYNDROME ARE USELESS (1996) (3)
Is there an association between maternal ABO and rhesus blood groups and the first‐trimester serum markers free β‐hCG and PAPP‐A used for the detection of fetal aneuploidy? (2007) (3)
First trimester screening for Down syndrome using free β hCG , total hCG and PAPPA : an exploratory study (2007) (2)
CT ratios: parameter estimates are inconsistent with SURUSS publications? (2006) (2)
The measurement of amniotic fluid alpha 2 macroglobulin by fixed time kinetic immunoturbidimetry. (1983) (2)
First and second‐trimester biochemical markers of chromosomal anomalies and their relationship to maternal haemoglobin levels (2005) (2)
Urine free beta-hCG and total estriol for Down syndrome screening during the second trimester in an Asian population. (1999) (2)
Can serial measurements of inhibin A and activin A be used to predict the outcome of pregnancies of unknown location (2008) (2)
The role of maternal serum α-fetoprotein in screening for open spina bifida at 11-13 weeks. (2014) (2)
Response to: Wald, N.J., Hackshaw, A.K. (1997). Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome, Prenat. Diagn., 17, 821-829. (1998) (1)
USE OF FREE BETA -HCG IN DOWN'S SYNDROME SCREENING. AUTHORS' REPLY (1993) (1)
155: Evolution of nuchal translucency (NT) measurements done by fetal medicine foundation-accredited sonographers in the US from 2003 to 2006 (2007) (1)
Precise bivariant normal distributions of maternal serum AFP and free bHCG for trisomy 21 (T21) biochemical screening (1997) (1)
Constraints on informed choice in a one-stop clinic for first trimester screening for Down's syndrome: a cross-sectional survey of women's experiences. (2007) (1)
OC38.03: One stop clinic for assessment of risk (OSCAR) for trisomy 21 in singleton pregnancies at 11 to 13 + 6 weeks of gestation (2005) (1)
First trimester maternal serum inhibin A concentrations in smokers (2013) (1)
Antenatal screening for Down's syndrome. (1993) (1)
OC090: The use of serial measurements of inhibin A and activin A to predict the outcome of pregnancies of unknown location (2008) (1)
Whole blood study Samples were collected from nine voluntary pregnant women during the second to third trimester of pregnancy (2010) (0)
First trimester prenatal diagnosis of trisomy 21 in discordant twins using fetal nuchal translucency thickness and maternal serum free b-hCG and PAPPA Screening for trisomy (0)
FIRST TRIMESTER BIOCHEMICAL SCREENING FOR TRISOMY 21 : THE ROLE OF FREE BETA -HCG AND PREGNANCY ASSOCIATED PLASMA PROTEIN. AUTHOR'S REPLY (1995) (0)
Undetectable pregnancy-associated plasma protein-A in antenatal serum Down’s syndrome screening: a case of assay interference (2015) (0)
Maternal Serum Neurone Specific Enolase in the Diagnosis of Anencephaly and other Neural Tube Defects (1988) (0)
Reply (2003) (0)
P01.12: Maintaining a nuchal translucency screening service—the role of systems analysis (2006) (0)
Potential misinterpretation of screening risk for trisomy 21 (1997) (0)
Authors' Reply (1993) (0)
Second‐trimester CA 125 and Down's syndrome (1993) (0)
OC042: Five years experience of screening for chromosomal anomalies in a 1st trimester OSCAR clinic (2003) (0)
Author's Reply (1995) (0)
OP14.01: Low 1st trimester PAPP-A and 2nd trimester uterine artery Dopplers in antenatal detection of SGA babies <10th centile (2015) (0)
Nuchal translucency and gestational age. Authors' reply (2004) (0)
Development of a light-scattering immunoassay for thyroxine-binding prealbumin in plasma or serum. (1984) (0)
First Trimester Serum Screening (2006) (0)
Chapter 9.8 – Pregnancy (2013) (0)
Response to “On gestational weeks and maths” (2013) (0)
Response: Hyperglycosylated hCG cannot be measured using a sialic acid–specific lectin immunoassay (2003) (0)
Response (2003) (0)
Stabilityof IntactChorionicGonadotropin (hCG) in Serum,LiquidWholeBlood,and DriedWhole-BloodFilter-PaperSpots:Impacton Screeningfor DownSyndromeby Measurementof Free f3-hCGSubunit (1993) (0)
[Comment on the contribution by Benz et al.: Serum screening for Down syndrome in women under 35 years of age with an age independent index]. (1995) (0)
Symposia Abstracts (2005) (0)
Authors' reply to Wierzbicki and Zimmermann (1994) (0)
P03.06: First‐trimester sonographic features of trisomy 13 (2005) (0)
The use of free beta-hCG in antenatal screening for Down's syndrome. (1994) (0)
MATERNAL SERUM FREE BETA HCG SCREENING. AUTHOR'S REPLY (1994) (0)
Estimating risk of Down's syndrome (1991) (0)
Chapter 21 – First Trimester Screening for Aneuploidy (2006) (0)
Women's experiences 1st trimester prenatal screening in a one stop clinic (2007) (0)
Prenatal screening for Down's syndrome: Authors' reply (1993) (0)

This paper list is powered by the following services:

Kevin M. Spencer's Academic­Influence.com Rankings

Kevin M. Spencer's Degrees

Why Is Kevin M. Spencer Influential?

Kevin M. Spencer's Published Works

Published Works

Kevin M. Spencer's AcademicInfluence.com Rankings